58 Unit Condo Development - Denver, CO

$16,100,000 loan arranged by PlattPointe Capital.

DENVER, CO - PlattPointe Capital arranged a $16.1mm non-recourse construction loan to develop a 58-unit residential for-sale condominium building in Denver, CO. The building's 58 units will be a mix of one-bedrooms, one-bedrooms with a den, two-bedrooms and mezzanine units, ranging from $339,000 on the low end to $617,750 for the mezzanine units.

The developer and general contractor, Doug Means of Anderson Construction Inc., is seeking to capitalize on growth along the South Broadway corridor with the project slated for delivery in the third quarter of 2020.

Loan Terms:
• $16,100,000 loan amount
• 18-month interest only loan
• Non-recourse to sponsorship
• No pre-sales required

About PlattPointe Capital:
PlattPointe Capital LLC is a boutique commercial real estate capital advisory firm that helps developers and investors navigate the capital markets by arranging optimal alternative debt and equity options for a client’s project. Our vision is to engineer the most efficient capital stack based on the constraints of a given project and sponsor’s needs.

More information can be found at www.sobo58.com and www.plattpointe.com.

For any inquiries nationwide, please contact:
Matthew Biegner


Units For Sale


Loan Amount


Pre-Sales Required


PlattPointe Capital Denver, CO
  • PlattPointe Facebook
  • PlattPointe Twitter
  • PlattPointe LinkedIn
  • PlattPointe Google+

© 2021 PlattPointe Capital LLC

©© Copyright

This Website is not intended to solicit commercial mortgage brokerage business in AZ, CA, CT, HI, IL, IN, LA, MI, MN, MT, NV, NJ, NY, NC, ND, PA, RI, SD, UT. The sole purpose of this Website is to provide information which could possibly be used by a person or entity to obtain business and commercial financing and does not function as a substitute for the advice of an investment advisor or attorney. You should consult with your own trusted financial professionals before making any investment decisions. Click here for further regulatory disclosures.